Related Experiment Video
Updated: Dec 23, 2025

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
The arrhythmogenic N53I variant subtly changes the structure and dynamics in the calmodulin N-terminal domain,
Christian Holt1, Louise Hamborg1, Kelvin Lau2
1Aalborg University, Department of Chemistry and Bioscience, 9220 Aalborg, Denmark.
Abstract:
Mutations in the genes encoding the highly conserved Ca2+-sensing protein calmodulin (CaM) cause severe cardiac arrhythmias, including catecholaminergic polymorphic ventricular tachycardia or long QT syndrome and sudden cardiac death. Most of the identified arrhythmogenic mutations reside in the C-terminal domain of CaM and mostly affect Ca2+-coordinating residues. One exception is the catecholaminergic polymorphic ventricular tachycardia-causing N53I substitution, which resides in the N-terminal domain (N-domain). It does not affect Ca2+ coordination and has only a minor impact on binding affinity toward Ca2+ and on other biophysical properties. Nevertheless, the N53I substitution dramatically affects CaM's ability to reduce the open probability of the cardiac ryanodine receptor (RyR2) while having no effect on the regulation of the plasmalemmal voltage-gated Ca2+ channel, Cav1.2. To gain more insight into the molecular disease mechanism of this mutant, we used NMR to investigate the structures and dynamics of both apo- and Ca2+-bound CaM-N53I in solution. We also solved the crystal structures of WT and N53I CaM in complex with the primary calmodulin-binding domain (CaMBD2) from RyR2 at 1.84-2.13 Å resolutions. We found that all structures of the arrhythmogenic CaM-N53I variant are highly similar to those of WT CaM. However, we noted that the N53I substitution exposes an additional hydrophobic surface and that the intramolecular dynamics of the protein are significantly altered such that they destabilize the CaM N-domain. We conclude that the N53I-induced changes alter the interaction of the CaM N-domain with RyR2 and thereby likely cause the arrhythmogenic phenotype of this mutation.
Insights
Mutations in calmodulin (CaM) cause heart arrhythmias. The N53I CaM mutation, affecting the N-domain, alters interactions with the cardiac ryanodine receptor (RyR2), leading to arrhythmias.
Area of Science:
- Molecular biology
- Cardiovascular research
- Protein dynamics
Background:
- Calmodulin (CaM) mutations are linked to severe cardiac arrhythmias like catecholaminergic polymorphic ventricular tachycardia.
- Most disease-causing mutations are in the C-terminal domain, but N53I is in the N-terminal domain and affects RyR2 regulation.
Purpose of the Study:
- To investigate the molecular mechanism of the arrhythmogenic N53I CaM mutation.
- To understand how N53I affects CaM's interaction with the cardiac ryanodine receptor (RyR2).
Main Methods:
- Nuclear Magnetic Resonance (NMR) spectroscopy to study apo- and Ca2+-bound CaM-N53I structures and dynamics.
- X-ray crystallography to determine the structures of wild-type (WT) and N53I CaM complexed with RyR2's calmodulin-binding domain (CaMBD2).
Main Results:
- The N53I mutation does not significantly alter Ca2+ binding or overall CaM structure compared to WT CaM.
- N53I substitution exposes a new hydrophobic surface and significantly alters intramolecular dynamics, destabilizing the CaM N-domain.
- While N53I affects RyR2 regulation, it does not impact CaV1.2 channel regulation.
Conclusions:
- The N53I mutation alters CaM's N-domain dynamics and its interaction with RyR2.
- These altered interactions are the likely cause of the N53I-induced cardiac arrhythmia phenotype.
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

